American biotechnology company Novavax has announced the start of the third and final phase of research on the effectiveness of its PREVENT-19 coronavirus vaccine in the United States and Mexico.
This is stated in a statement on the company’s website.
“With the COVID-19 pandemic raging around the world, this trial is an important step in building a global portfolio of safe and effective vaccines to protect the world’s population,” said Novavax President Stanley Erk.
The company noted that the first two phases of the Novavax vaccine study demonstrated that the vaccine elicits a sustained immune response, produces highly neutralizing antibodies against the virus, and is generally well-tolerated.
“We thank our colleagues and partners who continue to work with us to urgently move our manufacturing processes to an industrial scale, and we are grateful for the hard work and assistance from Operation Warp Speed, the US FDA, and the Mexican government,” reads in the statement.